Building a Diverse, Equitable, and Collaborative Biotech Research Ecosystem
Oct 12, 2021 6:00PM—7:00PM
Categories Biopharma & Therapeutics, Industry Partner Event, Industry Partner Events
In partnership with Women in Bio, BioPathways throughout 2021, will feature prominent female biotech founders, executives, and VCs.
About this event
Featuring Michelle Hoffmann, Executive Director, Chicago Biomedical Consortium
Michelle Hoffmann, Ph.D. has been serving since August of 2021 as the Executive Director of the Chicago Biomedical Consortium (CBC), a consortium of biomedical researchers across Northwestern, the University of Illinois at Chicago, and the University of Chicago that is generously supported by the Searle Funds at The Chicago Community Trust. The CBC’s mission is to stimulate collaboration among scientists to accelerate discovery that will transform biomedical research and improve the health of humankind. Prior to this role, from 2019-2021, Dr. Hoffmann was the Senior Vice President of Deep Tech at P33, a privately funded nonprofit charged with elevating Chicagoland’s innovation economy and driving inclusive economic growth.
Prior to P33, Dr. Hoffmann spent 15 years helping life sciences companies grow, most recently as a Senior Vice President at Boston based Back Bay Life Science Advisors, an integrated strategy and investment firm to global life science companies and their investors. During her 8 years at Back Bay, Dr. Hoffmann led projects for large, publicly traded companies, as well as small, private, venture backed health care and life sciences companies. Dr. Hoffmann also worked closely with Back Bay’s investment team on two large transactions: an epigenetics platform that was sold to Gilead Pharmaceuticals for $65M and an agent to combat acute kidney injury that was acquired by AbbVie for $110M. Previously, she was Senior Manager, Center for Health Solutions and Pharmaceutical Market Lead, at Deloitte Research. Dr. Hoffmann also worked for Leerink Swan Strategic Advisors as a consultant/project manager, Capgemini/LECG as a consultant in their life sciences healthcare practice and at Fuld+Company as a senior analyst in Fuld’s healthcare practice.
Dr. Hoffmann earned a Ph.D. in Molecular and Cellular Biology from the University of California Berkeley with Professor Joshua Kaplan and completed a postdoctoral fellowship at Brandeis University in the laboratory of Professor Gina Turrigiano.
BioPathways is a monthly event series, featuring prominent bioentrepreneurs, biotech executives, and biotech investors in a fireside chat.